Producing dedifferentiated, programmable stem cells of human monocytic origin using culture medium having M-CSF and IL-3, useful in treating cirrhosis, pancreatic insufficiency, kidney failure, cardiac infarction and stroke

摘要

Producing dedifferentiated, programmable stem cells of human monocytic origin, comprises isolating monocytes from human blood, propagating the monocytes in a culture medium which contains the cellular growth factor M-CSF, cultivating the monocytes, subsequently or simultaneously, in a culture medium containing IL-3 and obtaining the human adult dedifferentiated programmable stem cells by separating the cells from the culture medium. Independent claims are also included for: (1) dedifferentiated, programmable stem cells of human monocytic origin; (2) a pharmaceutical composition containing the dedifferentiated, programmable stem cells of (1); (3) differentiated, isolated, somatic target cells and/or target tissue, obtained by reprogramming the stem cells of (1), comprising the membrane-associated surface antigen CD14; and (4) implantable materials coated with the dedifferentiated, programmable stem cells of (1) or the somatic target cells and/or target tissue of (3).